Cala Health was named to TIME and Statista's World's Top HealthTech Companies 2026 list in the Medical Devices and Wearables category, based on financial performance, reputation and online engagement across 500 recognized companies. Its wrist-worn TAPS therapy delivers peripheral nerve stimulation for action hand tremor, with the Cala kIQ Plus system cleared by the FDA this year for essential tremor and Parkinson's disease. Non-pharmacological control of motor symptoms preserves functional independence, a primary determinant of healthspan in neurodegenerative conditions.
Key Points
- Wrist-worn nerve stimulation treats action tremor without systemic medication
- FDA cleared kIQ Plus for essential tremor and Parkinson's
- VA coverage at no cost; Medicare under local criteria
Longevity Analysis
Peripheral nerve stimulation targets the tremor network through the wrist rather than through systemic drug exposure, removing a source of cognitive and autonomic interference common to beta-blockers and anticonvulsants used in tremor management. Adaptive calibration positions the device as a reader of individual neural signaling patterns rather than a fixed-dose intervention, and its benefit depends on consistent daily use rather than episodic application. Maintaining fine motor control sustains eating, hydration, medication adherence and social participation — the functional substrate on which independent aging rests.
Original published by LT Wire.